HC Wainwright Has Bullish Forecast for NeuroPace Q3 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Equities research analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for shares of NeuroPace in a report released on Thursday, August 13th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.15) for the quarter, up from their prior estimate of ($0.16). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for NeuroPace’s Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.67) EPS.

NPCE has been the subject of several other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of NeuroPace in a report on Monday. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Mizuho started coverage on shares of NeuroPace in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $19.29.

NeuroPace Stock Down 4.2%

NASDAQ NPCE opened at $14.02 on Friday. NeuroPace has a 52 week low of $8.41 and a 52 week high of $19.60. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. The company has a market capitalization of $481.17 million, a P/E ratio of -24.60 and a beta of 1.92. The stock’s 50-day moving average price is $15.37 and its 200-day moving average price is $15.33.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.04. The business had revenue of $22.83 million during the quarter, compared to analyst estimates of $22.61 million. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%.

Institutional Trading of NeuroPace

Several institutional investors and hedge funds have recently added to or reduced their stakes in NPCE. Legal & General Group Plc boosted its stake in NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after purchasing an additional 1,239 shares during the period. Quantbot Technologies LP purchased a new position in shares of NeuroPace in the second quarter worth $35,000. Quarry LP boosted its position in shares of NeuroPace by 94.9% during the third quarter. Quarry LP now owns 3,845 shares of the company’s stock worth $40,000 after acquiring an additional 1,872 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of NeuroPace by 755.6% during the fourth quarter. New York State Common Retirement Fund now owns 7,700 shares of the company’s stock worth $119,000 after acquiring an additional 6,800 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in NeuroPace by 60.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,160 shares of the company’s stock valued at $147,000 after acquiring an additional 4,972 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.